| Dr Brian William Nolan, MD | |
|
1 Medical Center Dr, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756-1000 | |
| (603) 650-8670 | |
| (603) 650-4973 |
| Full Name | Dr Brian William Nolan |
|---|---|
| Gender | Male |
| Speciality | Vascular Surgery |
| Experience | 30 Years |
| Location | 1 Medical Center Dr, Lebanon, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144337569 | NPI | - | NPPES |
| 1010655 | Medicaid | VT | |
| 30204421 | Medicaid | NH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2086S0129X | Surgery - Vascular Surgery | 12398 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Maine Medical Center | Portland, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mainehealth | 7517860588 | 2067 |
| Maine Medical Partners | 9335043967 | 789 |
News Archive
Targeting telomeres, the protective caps at the end of all chromosomes that are critical to healthy cell function, T.A. Sciences' products activate an enzyme that can slow down and possibly reverse age- and lifestyle-related telomere shortening. Short telomeres can cause mutations and degradations to chromosomes leading to loss of cell functionality. Its inaugural product, TA-65 is the only proven product specifically focused on the telomerase activation market.
Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it has initiated PEARL-SC, the Phase 2b study of A-623, a novel inhibitor of B-Cell Activating Factor, or BAFF, for the treatment of Systemic Lupus Erythematosus (lupus). Lupus patients suffer from a chronic autoimmune disease, which often leads to severe skin rash, fatigue, joint pain, major organ complications, and cardiovascular disease.
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052 photodynamic therapy in 18 patients with localized prostate cancer.
A Link between the level of active DNA repair genes in melanoma tumours and the effectiveness of chemotherapy for skin cancer patients has been established for the first time by a team of scientists.The study, part-funded by Cancer Research UK and published in Clinical Cancer Research today (Friday), found that higher levels of DNA repair genes in melanoma tumours were associated with a poorer response to chemotherapy.
In symptom-free individuals, the detection of misfolded amyloid-β protein in the blood indicated a considerably higher risk of Alzheimer's disease - up to 14 years before a clinical diagnosis was made.
› Verified 5 days ago
| Entity Name | Maine Medical Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104921535 PECOS PAC ID: 9335043967 Enrollment ID: O20040331000274 |
News Archive
Targeting telomeres, the protective caps at the end of all chromosomes that are critical to healthy cell function, T.A. Sciences' products activate an enzyme that can slow down and possibly reverse age- and lifestyle-related telomere shortening. Short telomeres can cause mutations and degradations to chromosomes leading to loss of cell functionality. Its inaugural product, TA-65 is the only proven product specifically focused on the telomerase activation market.
Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it has initiated PEARL-SC, the Phase 2b study of A-623, a novel inhibitor of B-Cell Activating Factor, or BAFF, for the treatment of Systemic Lupus Erythematosus (lupus). Lupus patients suffer from a chronic autoimmune disease, which often leads to severe skin rash, fatigue, joint pain, major organ complications, and cardiovascular disease.
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052 photodynamic therapy in 18 patients with localized prostate cancer.
A Link between the level of active DNA repair genes in melanoma tumours and the effectiveness of chemotherapy for skin cancer patients has been established for the first time by a team of scientists.The study, part-funded by Cancer Research UK and published in Clinical Cancer Research today (Friday), found that higher levels of DNA repair genes in melanoma tumours were associated with a poorer response to chemotherapy.
In symptom-free individuals, the detection of misfolded amyloid-β protein in the blood indicated a considerably higher risk of Alzheimer's disease - up to 14 years before a clinical diagnosis was made.
› Verified 5 days ago
| Entity Name | Maine Medical Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285738310 PECOS PAC ID: 9335043967 Enrollment ID: O20040525000396 |
News Archive
Targeting telomeres, the protective caps at the end of all chromosomes that are critical to healthy cell function, T.A. Sciences' products activate an enzyme that can slow down and possibly reverse age- and lifestyle-related telomere shortening. Short telomeres can cause mutations and degradations to chromosomes leading to loss of cell functionality. Its inaugural product, TA-65 is the only proven product specifically focused on the telomerase activation market.
Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it has initiated PEARL-SC, the Phase 2b study of A-623, a novel inhibitor of B-Cell Activating Factor, or BAFF, for the treatment of Systemic Lupus Erythematosus (lupus). Lupus patients suffer from a chronic autoimmune disease, which often leads to severe skin rash, fatigue, joint pain, major organ complications, and cardiovascular disease.
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052 photodynamic therapy in 18 patients with localized prostate cancer.
A Link between the level of active DNA repair genes in melanoma tumours and the effectiveness of chemotherapy for skin cancer patients has been established for the first time by a team of scientists.The study, part-funded by Cancer Research UK and published in Clinical Cancer Research today (Friday), found that higher levels of DNA repair genes in melanoma tumours were associated with a poorer response to chemotherapy.
In symptom-free individuals, the detection of misfolded amyloid-β protein in the blood indicated a considerably higher risk of Alzheimer's disease - up to 14 years before a clinical diagnosis was made.
› Verified 5 days ago
| Entity Name | Mainehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790265502 PECOS PAC ID: 7517860588 Enrollment ID: O20040701000166 |
News Archive
Targeting telomeres, the protective caps at the end of all chromosomes that are critical to healthy cell function, T.A. Sciences' products activate an enzyme that can slow down and possibly reverse age- and lifestyle-related telomere shortening. Short telomeres can cause mutations and degradations to chromosomes leading to loss of cell functionality. Its inaugural product, TA-65 is the only proven product specifically focused on the telomerase activation market.
Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it has initiated PEARL-SC, the Phase 2b study of A-623, a novel inhibitor of B-Cell Activating Factor, or BAFF, for the treatment of Systemic Lupus Erythematosus (lupus). Lupus patients suffer from a chronic autoimmune disease, which often leads to severe skin rash, fatigue, joint pain, major organ complications, and cardiovascular disease.
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052 photodynamic therapy in 18 patients with localized prostate cancer.
A Link between the level of active DNA repair genes in melanoma tumours and the effectiveness of chemotherapy for skin cancer patients has been established for the first time by a team of scientists.The study, part-funded by Cancer Research UK and published in Clinical Cancer Research today (Friday), found that higher levels of DNA repair genes in melanoma tumours were associated with a poorer response to chemotherapy.
In symptom-free individuals, the detection of misfolded amyloid-β protein in the blood indicated a considerably higher risk of Alzheimer's disease - up to 14 years before a clinical diagnosis was made.
› Verified 5 days ago
| Entity Name | Southern Maine Health Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659392819 PECOS PAC ID: 0143208348 Enrollment ID: O20040713001060 |
News Archive
Targeting telomeres, the protective caps at the end of all chromosomes that are critical to healthy cell function, T.A. Sciences' products activate an enzyme that can slow down and possibly reverse age- and lifestyle-related telomere shortening. Short telomeres can cause mutations and degradations to chromosomes leading to loss of cell functionality. Its inaugural product, TA-65 is the only proven product specifically focused on the telomerase activation market.
Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it has initiated PEARL-SC, the Phase 2b study of A-623, a novel inhibitor of B-Cell Activating Factor, or BAFF, for the treatment of Systemic Lupus Erythematosus (lupus). Lupus patients suffer from a chronic autoimmune disease, which often leads to severe skin rash, fatigue, joint pain, major organ complications, and cardiovascular disease.
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052 photodynamic therapy in 18 patients with localized prostate cancer.
A Link between the level of active DNA repair genes in melanoma tumours and the effectiveness of chemotherapy for skin cancer patients has been established for the first time by a team of scientists.The study, part-funded by Cancer Research UK and published in Clinical Cancer Research today (Friday), found that higher levels of DNA repair genes in melanoma tumours were associated with a poorer response to chemotherapy.
In symptom-free individuals, the detection of misfolded amyloid-β protein in the blood indicated a considerably higher risk of Alzheimer's disease - up to 14 years before a clinical diagnosis was made.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Brian William Nolan, MD 1 Medical Center Dr, Lebanon, NH 03756-1000 Ph: (603) 650-8670 | Dr Brian William Nolan, MD 1 Medical Center Dr, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756-1000 Ph: (603) 650-8670 |
News Archive
Targeting telomeres, the protective caps at the end of all chromosomes that are critical to healthy cell function, T.A. Sciences' products activate an enzyme that can slow down and possibly reverse age- and lifestyle-related telomere shortening. Short telomeres can cause mutations and degradations to chromosomes leading to loss of cell functionality. Its inaugural product, TA-65 is the only proven product specifically focused on the telomerase activation market.
Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it has initiated PEARL-SC, the Phase 2b study of A-623, a novel inhibitor of B-Cell Activating Factor, or BAFF, for the treatment of Systemic Lupus Erythematosus (lupus). Lupus patients suffer from a chronic autoimmune disease, which often leads to severe skin rash, fatigue, joint pain, major organ complications, and cardiovascular disease.
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052 photodynamic therapy in 18 patients with localized prostate cancer.
A Link between the level of active DNA repair genes in melanoma tumours and the effectiveness of chemotherapy for skin cancer patients has been established for the first time by a team of scientists.The study, part-funded by Cancer Research UK and published in Clinical Cancer Research today (Friday), found that higher levels of DNA repair genes in melanoma tumours were associated with a poorer response to chemotherapy.
In symptom-free individuals, the detection of misfolded amyloid-β protein in the blood indicated a considerably higher risk of Alzheimer's disease - up to 14 years before a clinical diagnosis was made.
› Verified 5 days ago
Nikolaos Zacharias, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Vascular Surgery, Lebanon, NH 03756 Phone: 603-650-8677 | |
Juliana Castellano, MD, PHD Surgery Medicare: Accepting Medicare Assignments Practice Location: One Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-8693 | |
Gina Lynn Adrales, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-8113 Fax: 603-650-8030 | |
Astrid Gleaton, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-5000 | |
Stefanie Sueda, Surgery Medicare: Medicare Enrolled Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-5000 | |
Dr. James C Cooros, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-8050 | |
Dr. David H Stone, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Dhmc Department Of Surgery, Lebanon, NH 03756 Phone: 603-650-4682 Fax: 603-650-4973 |